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Abstract The incidence and prevalence of fungal infections
in Chile are unknown. Here, we have estimated the burden of
serious fungal diseases from data obtained from clinical re-
ports, WHO reports, Chilean census, OECD reports and com-
prehensive literature search available on PubMed and
SciELO, among other scientific resources. Due the lack of
official data about fungal diseases, frequencies were calculat-
ed based on the specific populations at risk. Recurrent
vulvovaginal candidiasis (>4 episodes/year) is estimated to
occur in 3108/100,000. Using a low international average rate
of 5/100,000, we estimate 878 candidaemia cases and 132
patients with intra-abdominal candidiasis. Due to the low in-
cidence of pulmonary tuberculosis (TB) in Chile, limited
numbers of patients with chronic pulmonary aspergillosis are
likely: a total of 1212, 25% following TB. Invasive aspergil-
losis is estimated to affect 296 patients following leukaemia
therapy, transplantation and chronic obstructive pulmonary
disease (COPD), 1.7/100,000. In addition, allergic
bronchopulmonary aspergillosis (ABPA) and severe asthma
with fungal sensitisation (SAFS) were estimated to be around
97.9/100,000 and 127/100,000 respectively, in 675,772 adult
asthmatics and 1700 CF patients. Given a 38,000 human im-
munodeficiency virus (HIV) population, with around 2189
new cases of acquired immune deficiency syndrome (AIDS)
annually, cryptococcal meningitis and Pneumocystis pneumo-
nia are estimated at 0.12/100,000 and 4.3/100,000, respective-
ly. In total, 325,000 (1.9%) people in Chile develop serious
fungal infections annually. Respiratory fungal disease pre-
dominates in Chile; a national action plan for fungal disease
is urgently needed, including epidemiological studies to vali-
date the estimates.
Introduction
The incidence of invasive fungal disease (IFD) as an impor-
tant cause of morbidity and mortality has increased dramati-
cally in recent years, particularly in immunocompromised pa-
tients [1]. Mortality associated with fungal diseases is substan-
tially higher than those reported for most viral or bacterial
diseases. Over 1 million people every year die due a fungal
infection [2]. Additionally, several infectious processes in im-
munocompetent people caused by unusual opportunistic fungi
have been described in recent years [3–5].
Themost frequent opportunistic, ubiquitous and cosmopol-
itan infections are candidiasis (caused by Candida species),
aspergillosis (caused by Aspergillus species) and
mucormycosis (caused by species of the Mucorales order)
[6]. Among the endemic mycoses such as histoplasmosis, blas-
tomycosis, coccidioidomycosis and paracoccidioidomycosis,
no autochthonous cases have been described in Chile [7], ex-
cept for tourists or immigrants.
In Chile, studies conducted to investigate the epidemiolo-
gy, evolution, genetics and therapeutic management of fungal
infections caused by opportunistic fungi are scarce. No com-
prehensive studies have been conducted on antifungal resis-
tance frequency or mechanisms including emerging species
involved in mycosis. Moreover, data about the burden of in-
vasive fungal diseases is limited due to the lack of surveillance
programmes. The aim of this work was to assemble all
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available data from reliable sources and estimate the incidence
and prevalence of fungal diseases in Chile.
Methods
In order to elucidate the serious fungal burden in Chile, we
performed an exhaustive search of epidemiological reports
with unsuccessful results. In order to estimate the fungal bur-
den, data derived from the Organisation for Economic Co-
operation and Development (OECD), World Health
Organization (WHO), the Joint United Nations Programme
on HIV/AIDS (UNAIDS), Chilean Ministry of Health
(AUGE Clinical Guides), the Public Health Institute of Chile
and local reports were used in the present study. When no data
existed, risk populations were used to estimate frequencies of
fungal infections, using the previously described methodolo-
gy by LIFE (http://www.LIFE-worldwide.org).
Results and discussion
Chile is a South American country, with a population of ap-
proximately 17.5 million, 23% being children under 15 years
old and 16% being women >60 years old (http://data.un.org/
CountryProfile.aspx?crName=chile; https://data.oecd.org/
c h i l e . h tm ) . Th e 2013 GDP was $15 , 7 32 . No
epidemiological reports were obtained from any of the
databases such as PubMed, MEDLINE, MedFacts etc.
Estimated numbers and rates of key serious fungal infections
per year are shown in Table 1.
Candida infections
Recurrent vulvovaginal candidiasis (>4 episodes/year) is esti-
mated to occur in ∼272,812 women (3108/100,000) between
the ages of 15 and 50 years. Using a low international average
rate of 5/100,000, we estimate 878 episodes of candidaemia,
including nearly 132 patients with intra-abdominal candidia-
sis. Unfortunately, and despite their low frequency, these are
associated with poor outcomes and high hospitalisation costs
due the prolonged stay plus antifungal treatments [8]. Also,
the incidence estimated in the present report constitutes the
lowest in Latin America, but as with other countries, is an
under-estimate of burden because blood culture is only
∼40% sensitive for the diagnosis of invasive candidiasis [9,
10] and worse still for intra-abdominal candidiasis [11, 12].
The low rate of candidaemia from Chile contrasts with those
reported from other South American countries [13]. A surveil-
lance national programme for candidaemia started 2 years
ago, so additional data are likely to emerge soon. Based on
our laboratory data, the species most prevalent in candidaemia
are Candida albicans, followed by C. parapsilosis complex
and C. glabrata/tropicalis (unpublished results). In this way,
our results agree with those recently published from Brazil
[14]. Also, a recent outbreak due to Candida parapsilosis
complex was observed in Chile, affecting mainly adults on
haemodialysis in ten centres of our country [15].
Table 1 Estimated burden of











Oesophageal candidiasis – 2650 – – – 2650 15
Oral candidiasis – 6750 – – – 6750 38
Candidaemia – – – 614 264 878 5
Candida peritonitis – – – – 132 132 0.8
Recurrent vaginal candidiasis
(>4 episodes per year)
272,812 – – – – 272,812 3108
ABPA – – 17,183 – – 17,183 97.9
SAFS – – 22,300 – – 22,300 127
Chronic pulmonary
aspergillosis
– – 1212 – – 1212 6.90
Invasive aspergillosis – – – 137 159 296 1.7
Cryptococcal meningitis – 22 – – – 22 0.12
Pneumocystis pneumonia – 766 – – – 766 4.3
Mucormycosis – – – – – 35 0.2
Total burden estimated ∼325,036
ABPA Allergic bronchopulmonary aspergillosis, SAFS Severe asthma with fungal sensitisation
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Based on the at-risk population, oesophageal and oral can-
didiasis were estimated in a total of around 2650 and 6750
cases, respectively; we have not been able to estimate the
numbers in cancer and other conditions.
Aspergillosis and severe asthma
Invasive aspergillosis (IA) was estimated in haematological
malignancy, after transplantation and in chronic obstructive
pulmonary disease (COPD) patients admitted to hospital as
being about ∼1.7/100,000. Using a population rate of
3/100,000 for acute myeloid leukaemia (527 patients a year)
and an annual incidence of 10% in this patient group and an
equal number of IA cases in all other leukaemia and lympho-
ma patients, we estimated 137 IA cases in these populations.
In addition, we found that there were ∼200 allogeneic haema-
tological stem cell transplant recipients, 270 renal, 22 lung, 21
heart and 85 liver transplants in 2014. These patients contrib-
ute an additional 33 IA patients annually, assuming attack
rates of 10, 1, 20, 6 and 4%, respectively. COPD is estimated
to affect 16.9% of the population over 40 years [16, 17]. Using
the rate of IA of 1.3% of admissions to hospital inMadrid, this
predicts 159 patients annually with IA in COPD patients,
many in intensive care [18]. There are an estimated 2989
patients with lung cancer in 2012 (Globoscan), and assuming
that IA occurs in 2.6% of cases [19], an additional 82 IA cases
would be anticipated annually.
Due the low incidence of pulmonary tuberculosis (TB) in
Chile (∼2185 cases in 2014, ∼8.9% in HIV-positive patients)
[20], we estimate 96 new chronic pulmonary aspergillosis
patients after TB each year and a 5-year period prevalence
of 303 patients. The proportion of all chronic pulmonary as-
pergillosis patients prior to TB varies by the frequency of TB,
and given the high rate of COPD and moderate rate of asthma
in Chile, we have used a 25% proportion attributable to TB.
This gives a total estimated prevalence of chronic pulmonary
aspergillosis of 1212 patients (6.9/100,000).
Approximately 5% of the adult Chilean population has
asthma [21]. Of these, about 10% probably have severe asth-
ma. If we assume that a conservative 33% have fungal sensi-
tisation [22, 23], then ∼22,300 patients with have severe asth-
ma with fungal sensitisation (SAFS) (127/100,000). Overall
sensitisation rates in asthma to Alternaria are documented in
Chile [24], but not to allergenic fungi, in severe asthma.
Allergic bronchopulmonary aspergillosis (ABPA) affects
about 2.5% of the 675,772 adult asthmatic patients, and is rare
in children, so 17,183 probably have ABPA. There is probably
some overlap between these groups as some patients with
ABPA have severe asthma and all are sensitised to
Aspergillus. Based on our data, the incidence and prevalence
of respiratory fungal infections are one of the lowest in Latin
American, contrasting with those reported for Brazil [25] and
the Dominican Republic [26]. However, the lack of a
prospective cohort study of ABPA or SAFS in Latin
America or Chile, and no fungal sensitisation data apart from
Alternaria spp., is a major limiting factor for our estimates.
Other infections
Given a 38,000 human immunodeficiency virus (HIV) popu-
lation, with around to 2189 new cases of acquired immune
deficiency syndrome (AIDS) annually, cryptococcal meningi-
tis and Pneumocystis pneumonia (PCP) are estimated at 0.12/
100,000 and 4.3/100,000, respectively. This is based on a rate
of 1% of new cases presenting with cryptococcal meningitis
and 35% presenting with PCP. We have not been able to esti-
mate PCP cases in non-HIV patients, although it is likely to be
similar to those in HIV, based on our experience and docu-
mentation in other countries. These estimates were also
among the lowest in South America, which contrasts with
those reported for Brazil (4.7/100,000 and 3.52/100,000, re-
spectively) [25] and Trinidad and Tobago (30/100,000 and
3.7/100,000, respectively) [27].
Other mycoses such as endemic fungal diseases were not
considered due the lack of autochthonous and confirmed
cases. In one local publication, Wolff reported an allochtho-
nous outbreak of histoplasmosis in a group of Chilean travel-
lers to the Ecuador jungle [28]. If the rate of mucormycosis is
0.2/100,000, we would expect 35 cases annually, primarily in
diabetic and immunocompromised patients.
We know from clinical experience that superficial fungal
infections of skin and mucosa are the most frequent mycoses
in Chile (tinea unguium, tinea pedis and tinea capitis). These
are primarily related to dermatophytes, followed by Candida
spp. and Malassezia spp. In the dermatophytes group, the
most prevalent aetiological agents are Trichophyton rubrum,
followed by T. mentagrophytes andMicrosporum canis. Other
Trichophyton species, such as T. tonsurans, are very rare and
mainly associated with tinea capitis in immigrants (unpub-
lished data, available in our Lab. Databank). There are no data
on fungal keratitis or tinea capitis, although cases are seen in
Chile.
Conclusions
The present study indicates that around 1.9% (∼325,000) of the
Chilean population is affected by serious fungal infections.
However, the estimation of fungal diseases presented in this
study may be under- (or over-)estimated. These estimates have
multiple limitations, the most important of which is a dearth of
local data on actual fungal disease rates in at-risk populations.
Another significant limitation is the incomplete nature of the
estimates: no data on fungal rhinosinusitis, on Pneumocystis
pneumonia (PCP) in non-human immunodeficiency virus
(HIV) patients, on oral and oesophageal candidiasis in non-
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HIV patients and others are available. Even when such data are
collected, routine clinical care underestimates the incidence and
prevalence of fungal disease because the key diagnostic test(s)
is(are) not requested by unsuspecting clinicians. Most key non-
culture diagnostic tests are available in Chile but not always
utilised to the maximum extent. In addition, data about fungal
diseases came mainly from central areas of our ‘long’ country.
No data on clinical cases, epidemiology and reports are available
from remote regions, contributing to the lack of knowledge about
the actual serious fungal disease burden.
To our knowledge, this study represents the first attempt at
a comprehensive estimation of the burden of fungal disease in
Chile. Hopefully, this rough and preliminary national burden
estimate will stimulate some epidemiological studies to better
document the actual burden of fungal diseases.
Further epidemiological studies are clearly needed to vali-
date and extend these estimates. This study is part of a world-
wide initiative lead by LIFE (http://www.life-worldwide.org/),
which has the aim of calculating the global fungal burden in
order to establish the importance of mycoses in public health
around the world.
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